Research programme: cancer immunotherapeutics - Aduro/Novartis

Drug Profile

Research programme: cancer immunotherapeutics - Aduro/Novartis

Alternative Names: CDNs - Aduro Biotech; LKZ 145

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aduro BioTech
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Aug 2017 Aduro Biotech receives patent allowance for cyclic dinucleotides (CDNs) in USA
  • 30 Mar 2015 CDN Technology licensed to Novartis worldwide for the treatment of Cancer
  • 03 Dec 2014 Preclinical trials in Cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top